Magic Mushrooms Help 6X More Smokers Quit Than Patches

Smokers trying to kick the habit just got a surprising new ally: magic mushrooms.

Researchers at Johns Hopkins University discovered that a single dose of psilocybin, the active ingredient in psychedelic mushrooms, helped people quit smoking at six times the rate of traditional nicotine patches. The findings could mark the first breakthrough in smoking cessation treatment in two decades.

The study followed 82 smokers over six months. Everyone received 13 weeks of cognitive behavioral therapy, but one group got psilocybin while the other used nicotine patches.

The results surprised even the researchers. At the six-month mark, 17 people in the psilocybin group had stayed smoke-free, compared to just four in the patch group.

"I was surprised by the sheer magnitude of the effect," says lead researcher Matthew Johnson, a psychiatry professor at Johns Hopkins. The study appeared Tuesday in JAMA Network Open.

During the treatment, participants took a high dose of pure psilocybin in a comfortable room with soft music and eye shades. Trained facilitators stayed with them throughout the experience, which lasted several hours.

The current options for quitting smoking aren't great. Even with medication and counseling, only 20% to 30% of people successfully quit in any given attempt. That means 70% return to smoking.

The market hasn't seen a new smoking cessation medication in 20 years. Right now, smokers can choose from seven treatments, mostly nicotine replacement products like gums and patches, plus two prescription medications.

Why This Inspires

What makes psilocybin different is how it works. Unlike patches or medications that target nicotine receptors, psilocybin appears to rewire how the brain communicates with itself.

Participants described experiencing a profound shift in perspective. "Rather than falling into the same stories, these same patterns, it seems that things are shaken up and they can step outside of that and try something different," Johnson explains.

The intensive therapeutic support likely played a crucial role too. "It's not the drug by itself here," says addiction psychiatrist Dr. Brian Barnett, who wasn't involved in the study. "It's really harnessing the neuroplastic and learning effects that happen after the exposure."

This research builds on a smaller trial Johnson conducted over 10 years ago with similar promising results. The National Institutes of Health has now funded a larger ongoing trial that includes a placebo group.

The findings still need replication in more diverse populations, but they offer hope for millions of Americans struggling with cigarette addiction. Smoking remains the leading cause of preventable death in the United States.

Researchers are also exploring psilocybin for alcohol dependence and other psychedelic treatments for opioid addiction. "This is cutting-edge work," says Barnett. "Smoking is still a massive public health problem."

For the 70% of smokers who can't quit with current treatments, this breakthrough might finally shake things up.